- Display 30 Products per page
Published: November 1, 2004 | Price: $3,500.00 – $7,000.00
The market for pain management products is growing at a brisk pace, with some segments moving ahead at over 20%. The future for specialized pharmaceutical and medical device products in this market is bright and new opportunities exist for emerging treatment modalities as well. The report presents the most up-to-date information about the top-producing pain management products in terms of revenues, and analyzes the market by specific pain sites as well. The report concentrates on the following application areas: Burn...Published: January 1, 2005 | Price: $3,000.00 – $6,000.00
The U.S. market for Over-the-Counter (OTC) Pain Medication presents an in-depth analysis of the performance of various analgesics, including non-steroidal anti-inflammatory drugs (NSAID) and topical products in the US market. The analysis captures the performance of the market players, categories and leading brands in terms of revenue growth and volume growth. It also identifies key issues, drivers, challenges, regulations and trends affecting the marketplace. The report provides a comprehensive analysis of the pain medication products that are currently in the...Published: January 15, 2005 | Price: $995.00 – $1,990.00
Despite the traditional notion that nothing therapeutic can be accomplished for the 1.5 million Americans with autism and the 2 million more throughout the world, there are pharmacologic approaches to the disease that are providing some help for patients and garnering revenues for drug companies. This Market Briefing reviews the market for drugs used in the treatment of autism and related disorers, including Antidepressants, Anti-Anxiety drugs, Anti-psychotics, Anti-convulsants, and CNS stimulants for ADHD-related symptoms, forecasting revenues through 2009 gloabally and...Published: February 1, 2005 | Price: $3,500.00 – $7,000.00
The world market for cancer therapeutics is growing at a brisk double-digit pace, with revenues surpassing $40 billion this year. This study looks at each therapeutic approach in turn, reporting and forecasting revenues from 2002 through 2009. Market share by leading competitor in each therapy type is estimated for the year 2004. Therapy types considered, include: Chemotherapy Hormone Therapy Radiation Therapy Immunotherapy and Biotherapy, and Adjunctive Therapies The study focuses on current and emerging markets, products in development, and trends...Published: April 1, 2005 | Price: $1,995.00 – $3,990.00
This timely overview of direct to consumer (DTC) pharmaceutical marketing examines the numerous issues surrounding DTC practices and markets, using industry and consumer publications as well as interviews with industry experts. The topics examined include: DTC marketing spending by product, DTC marketing spending by company DTC marketing spending by media channel The ROI debate on the cost-effectiveness of DTC marketing expenditures Arguments for and against DTC marketing by its proponents and critics DTC marketing regulations in the U.S. and selected...Published: April 1, 2005 | Price: $995.00 – $1,990.00
Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality. This briefing examines both corrent and emerging therapeutic approaches for the management of schizophrenia. It provides an analysis of the current and future markets for these agents, including forecasts to 2009 segmented by geographic region and by type of drug and likely market scenarios for new agents not yet available. The briefing discusses...Published: April 1, 2005 | Price: $3,500.00 – $7,000.00
The current market for diabetes products is large and growing. Both monitoring and therapeutic products have an excellent market outlook. Diabetes markets have long had major areas of unmet need, and that has not changed during the past several decades. In fact, the number of diabetic patients, especially in the United States, will increase at an accelerating rate over the next 20 years. With the recognition of diabetes as a public health issue of increasing importance, greater pressure will be...Published: April 1, 2005 | Price: $2,500.00 – $5,000.00
In the past 100 years, there has been a steady increase in the incidence of serious secondary systemic fungal infections. One of the factors aiding the spread of fungal disease has been the widespread use of broad-spectrum antibiotics, which eliminate or decrease the non-pathogenic bacterial populations that normally compete with fungi. Another has been the vast increase in populations with with compromised immune response (caused by AIDS or by the action of immunosuppressant drugs or cancer chemotherapy agents). In addition...Published: May 1, 2005 | Price: $3,000.00 – $6,000.00
Within the world of life science research, informatics plays a key role. A few years ago, this market space was occupied primarily by a few niche players, but over the past five years, established companies have expanded their offerings and hundreds of new software companies have surfaced. In the rapidly changing field of informatics, it is difficult to decode the buzz-words, interpret the extravagant claims, separate true needs from blue-sky wishes. The concerns and strategies of only a year ago...Published: May 1, 2005 | Price: $3,500.00 – $7,000.00
The worldwide market for prescription cardiovascular drugs encompasses a wide variety of products that treat the many facets of cardiovascular disease. The field of cardiology is currently experiencing a busy and dynamic period. As a result, the range of therapeutic options available to physicians has expanded significantly in the past few years and the development pipeline promises even more weapons soon. The sheer size and diversity of the current market and the potential of new products make this therapeutic category...Published: May 1, 2005 | Price: $2,500.00 – $5,000.00
For the past 60 years, antibiotic drugs have changed bacterial infections from the life-threatening scourges they once were into eminently treatable conditions. However, the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to traditional agents. As a result, pharmaceutical companies are taking a second look at the antibiotic market, after more than two decades of relative complacency. In addition to the scientific and technical challenges of new antibiotic development, there are significant...Published: May 1, 2005 | Price: $3,500.00 – $7,000.00
This study provides a comprehensive analysis of available and emerging reproductive products and technologies related to contraception and infertility treatments. The goal of this study is to provide a comprehensive range of information from detailed product analyses through industry trends, and to quantify and qualify the market for hormonal contraceptives, infertility pharmaceuticals, and for assisted reproductive technologies. The report forecasts the following markets through 2008: The world market oral contraceptives The world market hormonal contraceptive devices The world market infertility...Published: June 1, 2005 | Price: $2,500.00 – $5,000.00
This volume of Kalorama Information’s World Market for Anti-Infectives series focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease Inhibitors Other Misc. Antivirals The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides an An overview Description of products on the market Description of products in development Market estimates and forecasts through 2009 Market segmentation by infection type Market segmentation by geographic region Market share of leading...Published: July 1, 2005 | Price: $3,000.00 – $6,000.00
This report on the U.S. market for over-the-counter (OTC) cough, cold, sinus and allergy (CCSA) medication presents an in-depth analysis of the performance of various CCSA drugs in the U.S. market. The analysis captures the performance of the market players, drug categories, and leading brands in terms of revenues and growth. It also identifies key issues, drivers, challenges, regulations, and trends affecting the marketplace. In addition, the report provides a detailed analysis of consumer demographics and preferences in terms of...Published: August 1, 2005 | Price: $795.00 – $1,990.00
Neurological disease that impacts the sensory pathway can produce severe chronic pain, also known as neuropathic pain. This usually is unrelated to any peripheral tissue injury. This occurs with disorders of the central nervous system (CNS), such as stroke and multiple sclerosis, or with conditions associated with peripheral nerve damage, such as mechanical injury, diabetic neuropathy or herpes zoster infection. On form of neuropathic pain that is just now gaining recognistino is complex regional pain syndrome (CRPS), also known as...Published: August 1, 2005 | Price: $2,500.00 – $5,000.00
This market briefing concentrates on the U.S. market for medical nutritional support—in particular, the enteral and parenteral foods. The continuing development of equipment, medical foods, and feeding procedures that secure the nutrition of critically ill patents has greatly improved recovery and survival in select populations. Advances in the effectiveness and safety of nutritional procedures and techniques have evolved from steady improvements, including the use of antibiotic materials, biosensors, wireless communications, and more efficient pumps and controllers. These new developments have...Published: September 1, 2005 | Price: $3,500.00 – $7,000.00
Management of both acute and chronic neurologic diseases can be challenging for both the patient and the health care provider. Many neurologic disorders involve progressive deterioration in physical and mental capabilities, which can be devastating to the patient and the patient’s family. In many respects, neurotherapeutics represent the largest as-yet untapped market in medicine. This Kalorama Information report focuses on several key product segments of neurotherapeutic treatment: Alzheimer’s Disease and Other Dementias Brain and Neurologic Cancers Brain Trauma and Stroke...Published: October 1, 2005 | Price: $3,500.00 – $7,000.00
Cancer, with its high prevalence and mortality rate, continues to rank among the world's deadliest and most costly diseases. According to the WHO, in 2003, about 25 million people live with cancer and nearly 11 million new cases are diagnosed each year. With advances in protein and cell chemistry, genetics and molecular biology researchers are making continued progress in understanding the disease. Further, cancer drug research is moving from traditional cytotoxic chemotherapies toward higher specificity immunological and biological approaches that...Published: November 1, 2005 | Price: $2,500.00 – $5,000.00
Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, are set to lose patent protection in the United States in 2005 and soon after. This opens up a market currently worth over $30 billion (and growing at over 10% per year) to generic competition, if—and it’s a big if—the regulatory hurdles for these generics can be overcome. Biogeneric is a new term combining biologic...Published: November 1, 2005 | Price: $3,500.00 – $7,000.00
Although, the next 15-20 years will shift a majority of the population into the elderly population group, children will continue to remain the bulk of the dependent population worldwide with 9 in every 10 people falling into a pediatric age range in the less developed regions of Africa, Asia and Latin America. Therefore, the treatment of conditions and diseases affecting pediatrics and the healthy growth of children are vital to providing a solid foundation for healthy adults in the future....Published: January 1, 2006 | Price: $2,995.00 – $5,990.00
In the Spring of 2003, Kalorama published its first report on Outsourcing in Drug Discovery. Since then, so much has changed, the use of the term "2nd Edition" hardly seems appropriate. This new study involved completely re-examining the market from the ground up. This new report is designed to make readers aware of the enormous changes that are taking place in the drug discovery outsourcing market, and the forces that are shaping the sector. It presents viewpoints from both customers...Published: January 1, 2006 | Price: $3,000.00 – $6,000.00
The U.S. Market for OTC anti-infective products surpassed the $2 billion mark last year. Although overall growth is sluggish, the market is a proven revenue source for a number of major brands, and there have been some nice surprises in the performance of some categories, such as first-aid related antiseptic and antibiotic products. This comprehensive report examines all aspects of the U.S. OTC market, including 5-year sales performance by brand and by marketer for the following categories of products: Antifungals...Published: January 1, 2006 | Price: $995.00 – $5,990.00
With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products. As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will impose unprecedented demands on the industry’s biomanufacturing capacity. Whether or not this will create a biomanufacturing bottleneck is a hotly debated issue in the industry....Published: February 18, 2006 | Price: $2,200.00 – $5,990.00
Biopharmaceutical research and development is sure to dramatically increase the number of injectable drugs coming to market over the next few years. While advanced drug delivery techniques continue to hold promise for unique methods of administration, the traditional injection is still the dominant paradigm. However, the staggering costs and intransigent safety problems associated with sharps, along with consumer demand and the move to alternate-site care, are pushing for alternatives to traditional needles and syringes faster than advanced delivery technologies can...Published: February 1, 2006 | Price: $1,995.00 – $7,800.00
This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fifth time Kalorama Information has comprehensively studied the dermatology markets. As is the case with each new edition, Kalorama completely re-evaluated the market from the ground up, and in addition to the usual primary interviewing of industry participants, clinicians, and regulators, we also conducted scores of...Published: February 1, 2006 | Price: $3,000.00 – $6,000.00
The private label over-the-counter (OTC) market has been gaining ground rapidly over the past five years. The private label sector has shed its image of being a ‘me-too’ version of national brands and worked toward offering quality and innovation at an economical price. With benefits for consumers, retailers, and manufacturers, private label healthcare should experience solid growth through the end of the decade. This report on the U.S. market for OTC private label products presents an in-depth analysis of the...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
There are hundreds of drugs in Phase III clinical trials, of which almost 200 of them may gain market approval from the FDA in the coming 5 years. Which drugs will make it and how these drugs impact existing pharmaceutical markets in terms of overall size and competitive share is one of the most difficult forecasting projects in market research. In this nearly 500-page analysis, Kalorama Information has compiled all the relevant information about the candidates, their value, and their...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and evolving marketplace disruptions. For the development of a coherent strategy in this therapeutic area, companies must clearly focus on three...Published: April 1, 2006 | Price: $3,500.00 – $7,000.00
Adjunctive therapies are not only vital to the success of cancer treatments, enhancing compliance and outcomes, but they are also a dynamic area of research and development in a variety of disciplines from drug delivery to biologics. It also happens to be the largest portion of the overall cancer therapeutics market. This report provides the reader with a comprehensive analysis of the worldwide market for therapeutics to treat and manage symptoms in cancer patients. Market information, including market size and...Published: April 1, 2006 | Price: $2,500.00 – $7,000.00
The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent protection in the past few years of some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol....